Drug Profile
TAS 3681
Alternative Names: TAS-3681Latest Information Update: 14 Nov 2023
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 08 Nov 2023 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in France prior to November 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 08 Nov 2023 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in United Kingdom prior to November 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)
- 08 Nov 2023 Discontinued - Phase-I for Prostate cancer (Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA prior to November 2023 (PO) (Otsuka Pharmaceutical pipeline, November 2023)